SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Titan Pharmaceuticals (TTNP)

Add TTNP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator interstate, TRUTH, matthewverymuch, Ppower
Search This Board:
Last Post: 9/3/2015 10:07:08 AM - Followers: 160 - Board type: Free - Posts Today: 0



Probuphine®-This study is enrolling participants by invitation only.

Click For Link To

*November 20, 2014 -  the study is 100% enrolled. 
   * First patients enrolled on Jul 21, 2014 *                                  * DrKate Glassman-Beebe- Executive Vice President and Chief Development Officer-Titan Pharmaceuticals

Click For Link 


Braeburn Pharmaceuticals Identifier:
Information provided by (Responsible Party):
First received: July 1, 2014
Last updated: July 8, 2014
Last verified: July 2014
Braeburn Pharmaceuticals

Probuphine Graphic




Continuous Drug Delivery Technology


The continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (“EVA”) and a drug substance. The resulting product is a solid matrix that is placed subcutaneously, normally in the inner part of the upper arm in a simple office procedure, and is removed in a similar manner at the end of the treatment period. The drug substance is released slowly, at continuous levels, through the process of dissolution. This results in a stable blood level similar to intravenous administration. Such long-term, linear release characteristics are generally desirable as this avoids peak and trough level dosing that poses problems for many Central Nervous System (“CNS”) and other disease settings.

This continuous drug delivery technology was developed to address the need for a simple, practical method to potentially provide continuous drug administration on an outpatient basis over extended periods of up to 6-12 months. In addition to Probuphine, which is the first product to complete clinical testing that has utilized this proprietary continuous drug delivery technology, Titan has conducted initial non-clinical studies with long-term delivery of dopamine agonists demonstrating the potential of this product in the treatment of Parkinson’s disease in non-clinical models of the disease.


Fanapt® (iloperidone)


Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia currently being marketed by Novartis Pharma AG (“Novartis”) in the U.S. Titan is entitled to a royalty of 8-10% of net sales of Fanapt under a sublicense agreement with Novartis that is based on a U.S. patent which expires in October 2016 (does not include a possible six-month pediatric extension).

Titan has entered into several agreements with Deerfield Management LP (“Deerfield”), which entitle Deerfield to most of the future royalty revenues related to Fanapt in exchange for cash and debt considerations, the proceeds of which have been used to advance the development of Probuphine and for general corporate purposes. Titan has retained a portion of the royalty revenue from net sales of Fanapt in excess of specified annual threshold levels; however, based on sales levels to date, it is unlikely that Titan will retain any revenue from Fanapt in the next several years, if ever. Titan does not incur any ongoing expenses associated with this product.

Company Overview

Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. It is currently marketed in the U.S. by Novartis Pharma, AG, and Titan is entitled to receive 8-10% of global annual sales as royalty revenue for the term of the licensed patents.


Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction. Probuphine is a novel, subcutaneous implant formulation of buprenorphine designed to deliver six months of medication following single treatment. This product has already demonstrated strong positive results in the first controlled Phase 3 study for the treatment of opioid addiction. The confirmatory Phase 3 study is currently being conducted at 20 sites in the U.S., and the results of this study are expected in Q2, 2011. Additional information on the Probuphine program is available in the PRODUCTS section of this website.


The Company's common stock is traded on the OTC Bulletin Board Markets ([TTNP.OB] quotations system. For further information please contact


Management Team

Sunil Bhonsle, M.B.A.

Executive Vice President and Chief Development Officer

Katherine L. Beebe, Ph.D.

Executive Chairman

Marc Rubin, M.D.


Board of Directors



Strategic Alliances

In December 2012, Titan entered into a license agreement with Braeburn Pharmaceuticals Sprl (“Braeburn”) that grants Braeburn exclusive commercialization rights to Probuphine® in the United States and Canada. Titan received a non-refundable up-front license fee of $15.75 million and will receive a $50 million milestone payment upon the approval of the NDA by the FDA. Additionally, Titan will be eligible to receive up to $130 million upon achievement of specified sales milestones and up to $35 million in regulatory milestones in the event of future NDA submissions and approvals for additional indications, including chronic pain. Titan will receive tiered royalties on net sales of Probuphine ranging from the mid-teens to the low twenties.


Product Overview

The investigational products are at various stages of development as listed below.

Titan Pharmaceuticals Products



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TTNP News: Statement of Changes in Beneficial Ownership (4) 08/31/2015 05:20:49 PM
TTNP News: Statement of Changes in Beneficial Ownership (4) 08/26/2015 02:25:01 PM
TTNP News: Current Report Filing (8-k) 08/25/2015 04:12:34 PM
TTNP News: Quarterly Report (10-q) 08/13/2015 06:20:54 PM
TTNP News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/11/2015 05:08:29 PM
#5431  Sticky Note From brae's website... matthewverymuch 06/08/15 08:17:08 AM
#5986   TTNP has 6 months until FDA decision day... interstate 09/03/15 10:07:08 AM
#5985   It's going to happen when we turks 09/03/15 12:19:02 AM
#5984   V O L U M E....V O L Chia 09/02/15 10:34:18 PM
#5983   You better believe they'll be there,now with everything turks 09/02/15 06:21:47 PM
#5982   I saw a tweet that Titan was attending BillCat 09/02/15 04:26:47 PM
#5981   Hey it is a start... Insider bought 100K interstate 09/01/15 11:16:52 AM
#5980   Yes, .......seems to be a little faith amongst Chia 09/01/15 09:19:15 AM
#5979   Wow,right again knew he was buying,right turks 08/31/15 08:24:28 PM
#5978   Marc Rubin just purchased 50,000 shares at an exdaytrader777 08/31/15 07:42:50 PM
#5977   Don't count on that for second happening before Rentier 08/31/15 06:26:58 PM
#5976   What a joke the pps.but....but a great turks 08/31/15 04:16:18 PM
#5975   Matt,they won't or shouldn't do a RS at turks 08/31/15 01:40:12 PM
#5974 the r/s...let it drop 40%, then build matthewverymuch 08/31/15 12:44:44 PM
#5973   Now we need to get the R/S out interstate 08/31/15 12:31:33 PM
#5972   It's amazing that we get great turks 08/31/15 11:27:58 AM
#5971   I would guess that with the majority of Chia 08/31/15 11:20:04 AM
#5970   This is what I was saying and hoping turks 08/31/15 10:51:36 AM
#5969   Could be sooner than six months.... TRUTH 08/31/15 09:14:24 AM
#5968   It appears that Braeburn has done everything from TRUTH 08/31/15 09:09:59 AM
#5967   I do not look for too much right interstate 08/31/15 08:49:32 AM
#5966   With a month to spare...we shall see what matthewverymuch 08/31/15 08:42:40 AM
#5965   It is about time... TTNP made true to interstate 08/31/15 08:41:06 AM
#5964   Nda submitted..! matthewverymuch 08/31/15 07:53:55 AM
#5963   Have a feeling that the other board members turks 08/28/15 05:00:48 PM
#5962   I have posted my math many times and interstate 08/27/15 08:23:33 PM
#5961   did that spot speculators from taking it to Rentier 08/27/15 06:01:44 PM
#5960   Sunil Purchased 50,000 shares Doctor Detroit 08/27/15 11:08:15 AM
#5959   My math is spot on. It doesn't interstate 08/27/15 09:34:32 AM
#5958   No they didn't and no they won't, you Rentier 08/26/15 07:08:57 PM
#5957   Yep, they already said they want to do Rentier 08/26/15 07:06:33 PM
#5956   That is not even close to true. Rentier 08/26/15 07:03:04 PM
#5955   for the right reasons. Did TTNP do it TRUTH 08/26/15 06:31:55 PM
#5954   I understand... I am just saying that all interstate 08/26/15 06:19:50 PM
#5953   If Probuphine doesn't get approved, all these "theatrics" TRUTH 08/26/15 06:14:02 PM
#5952   Yes and it is still up 33%... Do interstate 08/26/15 06:01:21 PM
#5951   I'm alluding to the fact that ZGNX waited TRUTH 08/26/15 05:59:37 PM
#5950   See R/S are not always bad. People interstate 08/26/15 05:55:34 PM
#5949   Check out ZGNX pre and post reverse split.... TRUTH 08/26/15 05:49:34 PM
#5948   Doesn't really matter to me if they get TRUTH 08/26/15 05:46:41 PM
#5947   Maybe to Institutions... but if they are sold interstate 08/26/15 05:39:36 PM
#5946   Sunil explained that institutions would be able to TRUTH 08/26/15 05:37:06 PM
#5945   It also looks like some inside buying as well. interstate 08/26/15 03:42:15 PM
#5944   It is not artificial or fake. It interstate 08/26/15 03:39:52 PM
#5943   Look at DVAX since their R/S interstate 08/26/15 03:35:36 PM
#5942   Like i said, why would institutions invest in matthewverymuch 08/26/15 03:34:18 PM
#5941   It should matter. With the NASDAQ, comes interstate 08/26/15 03:12:02 PM
#5940   So, if I have 4,000 shares at .70 ekmey 08/26/15 02:58:24 PM
#5939   Doesn't really matter to me if they get matthewverymuch 08/26/15 02:22:20 PM
#5938   I hate to tell you but with the interstate 08/26/15 02:04:26 PM
#5937   It is a negative. It is a cheap matthewverymuch 08/26/15 01:51:39 PM